Childhood Germ Cell Tumor, Ovarian Cancer, Teratoma
Conditions
Keywords
childhood extragonadal germ cell tumor, childhood malignant ovarian germ cell tumor, childhood malignant testicular germ cell tumor, stage III malignant testicular germ cell tumor, testicular choriocarcinoma and seminoma, testicular embryonal carcinoma and seminoma, testicular embryonal carcinoma and teratoma with seminoma, testicular embryonal carcinoma and yolk sac tumor with seminoma, testicular yolk sac tumor and teratoma with seminoma, testicular choriocarcinoma and embryonal carcinoma, testicular choriocarcinoma and teratoma, testicular choriocarcinoma and yolk sac tumor, testicular choriocarcinoma, testicular embryonal carcinoma and teratoma, testicular embryonal carcinoma and yolk sac tumor, testicular embryonal carcinoma, testicular yolk sac tumor and teratoma, testicular yolk sac tumor, testicular seminoma, stage IV extragonadal non-seminomatous germ cell tumor, stage IV extragonadal seminoma, stage I extragonadal non-seminomatous germ cell tumor, stage I extragonadal seminoma, stage II extragonadal non-seminomatous germ cell tumor, stage II extragonadal seminoma, stage III extragonadal non-seminomatous germ cell tumor, stage III extragonadal seminoma, stage II ovarian germ cell tumor, stage I malignant testicular germ cell tumor, stage II malignant testicular germ cell tumor, adult teratoma, childhood teratoma, testicular immature teratoma, testicular mature teratoma, adult central nervous system germ cell tumor, childhood central nervous system germ cell tumor
Brief summary
RATIONALE: Germ cell tumors (GCT) are highly sensitive to chemotherapy such that even with metastatic disease at diagnosis, many patients can be cured. Patients who fall into the poor risk category or others who relapse can be successfully salvaged with high dose chemotherapy and autologous stem cell transplant (AuSCT). As in other diseases such as myeloma, sequential high dose chemotherapy and AuSCT may improve overall and disease free survival. PURPOSE: Because prior investigations in GCT suggest that a subset of high risk or relapsed patients may be cured with sequential cycles of high dose chemotherapy and AuSCT, we propose investigating how well non-cross resistant conditioning regimens work in treating patients with relapsed or high risk GCT.
Detailed description
OBJECTIVES: Primary * Determine overall survival (OS) of patients with germ cell tumors treated with tandem autologous stem cell transplantation with non-cross-resistant conditioning regimens. Secondary * Determine disease-free survival (DFS) of patients treated with this regimen. * Determine the toxicity of tandem transplants * Determine the time to engraftment of neutrophils and platelets in patients treated for each transplant * Determine the number of patients unable to adequately mobilize sufficient peripheral blood stem cells (PBSC) for tandem transplantation. * Identify prognostic factors of patients unlikely to mobilize sufficient PBSC for tandem transplantation. * Compare OS and DFS of patients undergoing single vs tandem transplantation. OUTLINE: * Peripheral blood stem cell (PBSC) mobilization with filgrastim (G-CSF): Patients receive G-CSF subcutaneously (SC) beginning on day 1 and continuing until stem cell collection is complete. Patients undergo stem cell collection beginning on day 5 of G-CSF administration and continuing for at least 3 collections until the collection goal is met. * Second PBSC mobilization with chemotherapy: Patients not meeting the collection goal receive cyclophosphamide IV over 2 hours on day 1 and G-CSF SC beginning on day 4 and continuing until stem cell collection is complete. Patients meeting the collection goal after PBSC mobilization via G-CSF alone or in combination with chemotherapy will undergo tandem autologous transplantation. If collection goal is not met but the patient has collected \> or = 2 x 10\^6 CD34 cells/kg, a single autologous transplant will be performed. * Single stem cell transplantation (SCT): Patients receive paclitaxel IV over 3 hours on day -7 and ifosfamide IV on days -6 to -4. Patients undergo reinfusion of stem cells on day 0. Patients also receive G-CSF SC or IV beginning on day 1 and continuing until blood counts recover. * Tandem SCT: Patients receive treatment as in single SCT. Beginning 30-90 days later, patients receive carboplatin IV over 60 minutes and thiotepa IV over 30 minutes on days -6 to -4 and etoposide IV over 60 minutes on days -6 to -3. Patients undergo reinfusion of stem cells on day 0. Patients also receive G-CSF SC or IV beginning on day 5 and continuing until blood counts recover. After completion of study treatment, patients are followed at 6, 9, and 12 months and then every 6 months for up to 2 years. PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study.
Interventions
DRUGcarboplatin
Days -6, -5, -4: 500mg/m2\^/day intravenously (IV) over 60 minutes
DRUGetoposide
600mg/m\^2/day intravenously (IV) over 60 minutes on Days -6 through -3.
DRUGifosfamide
2500 mg/m\^2/day continuous infusion intravenously on Days -6, -5 and -4.
DRUGpaclitaxel
225 mg/m\^2 intravenous over 3 hours on Day -7.
DRUGthiotepa
150mg/m\^2/day intravenously IV over 30 minutes; Days -6, -5 and -4
PROCEDUREautologous hematopoietic stem cell transplantation
Peripheral blood stem cell infusion (\< 4 x 10\^6 CD34+ cells/kg)
DRUGMesna
2500 mg/m\^2/day continuous infusion intravenously on Days -6, -5 and -4.
BIOLOGICALfilgrastim
Beginning Day 5, G-CSF 5 μg/kg/day until absolute neutrophil count (ANC) ≥ 1500/UL for 3 consecutive days.
Sponsors
Masonic Cancer Center, University of Minnesota
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This trial is single arm study and it is non-randomized. Overall, if patients did not have enough cells to do two transplants then they only received one transplants.
Eligibility
Sex/Gender
ALL
Age
10 Years to 69 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis: Poor Prognosis Non-Seminomas Germ Cell Tumor in ≥ PR1/CR1 or Good or Intermediate Prognosis Seminomas and Non- Seminomas Germ Cell Tumor in ≥ PR1 or ≥ CR2 as defined by the International Germ Cell Cancer Consensus Classification. Patients with increasing tumor markers only (i.e. no imaging evidence of progressive disease) are eligible for transplant. * Age: ≥ 10 years and \< 70 years of age. * Performance status: Karnofsky ≥ 80% (subjects ≥ 16 years of age) Lansky ≥ 80% for subject 10 - 15 years of age * Life expectancy: Greater than 8 weeks. * Patients must have normal organ function as defined below: * Hematologic: * Hemoglobin \> 8 gm/dL without transfusion and off erythropoietin for 14 days or Aranesp for 21 days * White blood cells (WBC) \> 2.5 x 10\^9/L with an absolute neutrophile count (ANC) \> 1.5 x 10\^9/L and off G-CSF or GM-CSF for 10 days or Neulasta for 21 days * Platelets \> 100 x 10\^9/L without transfusion and/or a bone marrow cellularity of ≥ 20% * Renal: Creatinine ≤ 2.0 mg/dl or creatinine clearance \> 50 ml/min. * Hepatic: Total bilirubin ≤ 2.0 mg/dl, AST and alkaline phosphatase \< 5 x upper limit of normal. No history of severe prior or ongoing chronic liver disease. * Cardiac: Patients must be free of symptoms of uncontrolled cardiac disease including unstable angina, decompensated congestive heart failure, or arrhythmia. LVEF ≥45% by MUGA/ECHO. * Pulmonary: Patients must have no significant obstructive airways disease (FEV1 must be ≥ 50% of predicted) and must have acceptable diffusion capacity (corrected DLCO \> 50% of predicted). * Patients with a history of CNS tumor involvement are eligible if they have completed treatment for CNS disease (radiotherapy or surgery or chemotherapy), have recovered from or stabilization of the side effects associated with the therapy and have no evidence of progressive CNS disease at the time of enrollment.
Exclusion criteria
* Patients with serious uncontrolled infections will not be eligible. * Male and female patients of reproductive potential must use an approved contraceptive method if appropriate (for example, intrauterine device \[IUD\], birth control pills, or barrier device) during and for the duration of study participation. The drugs used in this study are pregnancy category D - clear evidence of risk in pregnancy. * Pregnant and breast feeding women will not be eligible. Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care. Additional Eligibility prior to Transplant Two: * Total Collection of ≥ 4 x 10\^6 CD34 cells/kg prior to transplant one * Transplant able to occur between day +30 and day +90 from transplant one * Recovery of blood counts as demonstrated by: * WBC \> 2.5 x 10\^9/L with an ANC \> 1.5 x 10\^9/L and off G-CSF for 3 days * Platelets \> 50 x 10\^9/L without transfusion in the prior 7 days * Renal: Creatinine ≤ 2.0 mg/dl or creatinine clearance \> 50 ml/min * Hepatic: Total bilirubin ≤ 2.0 mg/dl, AST and alkaline phosphatase \< 5 x upper limit of normal * Infection: Patients with serious uncontrolled infections at the time of planned transplant will be excluded * Patients with progressive disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria by imaging techniques are not eligible to proceed to the second transplant. Tumor marker increase alone is not sufficient to diagnose disease progression.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | 1 Year | The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer. Also called survival rate. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease-free Survival (DFS) | 1 Year | The number of patients who survive without any signs of symptions of that cancer or any other cancer. |
| Engraftment of Platelets | Day 100 | Platelet engraftment is defined as 20,000/mm\^3 (20 x 10\^9/L) for 3 consecutive days unsupported by a platelet transfusion. |
| Numbers of Patients Unable to Mobilize Peripheral Blood Stem Cells | Pre-Transplant | Number of patients unable to achieve adequate stem cell mobilization, need to undergo one or tandem transplantation. Stem cell mobilization = A process in which certain drugs are used to cause the movement of stem cells from the bone marrow into the blood. The stem cells can be collected and stored. They may be used later to replace the bone marrow during a stem cell transplant. |
| Engraftment of Neutrophils | Day 42 | Neutrophil engraftment is defined as the first day of three consecutive days where the neutrophil count (absolute neutrophil count) is 500 cells/mm3 (0.5 x 109/L) or greater. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| 2 Transplants/1 Transplant Arms (Overall) Patients with Germ Cell Tumors (GCT) treated with one and second autologous stem cell transplant (AuSCT) with non-cross-resistant conditioning regimens. | 23 |
| Total | 23 |
Baseline characteristics
| Characteristic | 2 Transplants/1 Transplant Arms (Overall) |
|---|---|
| Age, Continuous | 31 years |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 3 Participants |
| Race (NIH/OMB) White | 18 Participants |
| Sex: Female, Male Female | 4 Participants |
| Sex: Female, Male Male | 19 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 6 / 23 |
| other Total, other adverse events | 0 / 23 |
| serious Total, serious adverse events | 8 / 23 |
Outcome results
Primary
Overall Survival (OS)
The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer. Also called survival rate.
Time frame: 1 Year
Population: The protocol is essentially one single-arm, but patients received either one or two transplants depending on the cells they had available and we are reporting results for these two groups.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| 2 Transplants | Overall Survival (OS) | 86 percentage of participants |
| 1 Transplant | Overall Survival (OS) | 56 percentage of participants |
Secondary
Disease-free Survival (DFS)
The number of patients who survive without any signs of symptions of that cancer or any other cancer.
Time frame: 1 Year
Population: The protocol is essentially one single-arm, but patients received either one or two transplants depending on the cells they had available and we are reporting results for these two groups.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| 2 Transplants | Disease-free Survival (DFS) | 64 percentage of participants |
| 1 Transplant | Disease-free Survival (DFS) | 44 percentage of participants |
Secondary
Engraftment of Neutrophils
Neutrophil engraftment is defined as the first day of three consecutive days where the neutrophil count (absolute neutrophil count) is 500 cells/mm3 (0.5 x 109/L) or greater.
Time frame: Day 42
Population: The protocol is essentially one single-arm, but patients received either one or two transplants depending on the cells they had available and we are reporting results for these two groups.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| 2 Transplants | Engraftment of Neutrophils | 13 Participants |
| 1 Transplant | Engraftment of Neutrophils | 9 Participants |
Secondary
Engraftment of Platelets
Platelet engraftment is defined as 20,000/mm\^3 (20 x 10\^9/L) for 3 consecutive days unsupported by a platelet transfusion.
Time frame: Day 100
Population: The protocol is essentially one single-arm, but patients received either one or two transplants depending on the cells they had available and we are reporting results for these two groups.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 2 Transplants | Engraftment of Platelets | 13 participants |
| 1 Transplant | Engraftment of Platelets | 8 participants |
Secondary
Numbers of Patients Unable to Mobilize Peripheral Blood Stem Cells
Number of patients unable to achieve adequate stem cell mobilization, need to undergo one or tandem transplantation. Stem cell mobilization = A process in which certain drugs are used to cause the movement of stem cells from the bone marrow into the blood. The stem cells can be collected and stored. They may be used later to replace the bone marrow during a stem cell transplant.
Time frame: Pre-Transplant
Population: The protocol is essentially one single-arm, but patients received either one or two transplants depending on the cells they had available and we are reporting results for these two groups.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| 2 Transplants | Numbers of Patients Unable to Mobilize Peripheral Blood Stem Cells | 0 Participants |
| 1 Transplant | Numbers of Patients Unable to Mobilize Peripheral Blood Stem Cells | 0 Participants |